Autoimmune phenomena following SARS-CoV-2 vaccination

Area of Science:

• Immunology
• Vaccinology
• Public Health

Background:

• The COVID-19 pandemic necessitated rapid vaccine development and deployment.
• Public hesitancy due to potential side effects remains a barrier to widespread vaccine uptake.
• Israel's high vaccination rate provides a unique setting to observe rare vaccine-associated adverse events.

Observation:

• A series of patients developed new or flared autoimmune conditions post-Pfizer-BioNTech SARS-CoV-2 vaccination.
• These patients had no prior SARS-CoV-2 infection and were treated at an Israeli tertiary care center.
• The observed immune phenomena were associated with the BNT162b2 mRNA vaccine.

Findings:

• Autoimmune conditions, de novo or flares, were observed in a subset of vaccinated individuals.
• The majority of these immune events followed a mild clinical course.
• Modest therapeutic interventions were generally sufficient for managing these post-vaccination autoimmune phenomena.

Implications:

• While rare, SARS-CoV-2 vaccination can be associated with immune-mediated conditions.
• Understanding vaccine-related autoimmunity is crucial for addressing public concerns and ensuring vaccine confidence.
• Further research into the mechanisms and long-term outcomes of vaccine-induced autoimmunity is warranted.